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ABSTRACT
Objectives Current guidelines do not recommend direct 
oral anticoagulants (DOACs) to treat cerebral venous 
thrombosis (CVT) despite their benefits over standard 
therapy. We performed a systematic review to summarise 
the published experience of DOAC therapy in CVT.
Data sources MEDLINE, Embase and COCHRANE 
databases up to 18 November 2020.
Eligibility criteria All published articles of patients with 
CVT treated with DOAC were included. Studies without 
follow- up information were excluded.
Data extraction and synthesis Two independent 
reviewers screened articles and extracted data. A risk of 
bias analysis was performed.
Primary and secondary outcome measures Safety 
data included mortality, intracranial haemorrhage (ICH) 
or other adverse events. Efficacy data included recurrent 
CVT, recanalisation rates and disability by modified Rankin 
Scales (mRS).
Results 33 studies met inclusion criteria. One randomised 
controlled trial, 5 observational cohorts and 27 case series 
or studies reported 279 patients treated with DOAC for 
CVT: 41% dabigatran, 47% rivaroxaban, 10% apixaban 
and 2% edoxaban, in addition to 315 patients treated with 
standard therapy. The observational cohorts showed a 
similar risk of death in DOAC and standard therapy arms 
(RR 2.12, 95% CI 0.29 to 15.59). New ICH was reported 
in 2 (0.7%) DOAC- treated patients and recurrent CVT 
occurred in 4 (1.5%). A favourable mRS between 0 and 2 
was reported in 94% of DOAC- treated patients, more likely 
than standard therapy in observational cohorts (RR 1.13, 
95% CI 1.02 to 1.25).
Conclusion The evidence for DOAC use in CVT is limited 
although suggests sufficient safety and efficacy despite 
variability in timing and dose of treatment. This systematic 
review highlights that further rigorous trials are needed to 
validate these findings and to determine optimal treatment 
regimens.
INTRODUCTION
Cerebral venous thrombosis (CVT) requires 
rapid treatment to prevent neurological 
disability or death due to venous infarct and 
haemorrhage. The estimated incidence is 
1 per 100 000 per year with a mean age of 
onset 39 years.1 Although the mortality rate 
has reduced to 5%–15% due to advances in 
detection and treatment, morbidity rates 
can reach as high as 20%–30%.2 A Cochrane 
review in 2011 showed anticoagulation to be 
safe in CVT and was associated with a reduc-
tion in death prompting international guide-
lines to recommend acute treatment of CVT 
with either unfractionated heparin (UFH) or 
low molecular weight heparin (LMWH).3–6 
Longer term anticoagulation is required 
since recurrent venous thromboembolism 
(VTE) is highest within the first year of CVT.7 
Thus, at least 3 months of ongoing anticoag-
ulation in low- risk patients and indefinitely 
for unprovoked, high- risk patients, or those 
with malignancy, is recommended.6 8 The 
transition from acute treatment of CVT with 
LMWH or UFH to an oral anticoagulant, 
such as warfarin, is standard practice despite 
no randomised controlled trial (RCT) 
comparing warfarin with UFH or LMWH.
Direct oral anticoagulants (DOACs) were 
introduced to treat symptomatic VTE over 
the past 10 years and have advantages over 
warfarin: more predictable pharmacoki-
netics, no international normalised ratio 
(INR) monitoring requirement or daily dose 
adjustments, while demonstrating similar 
Strengths and limitations of this study
 ► We performed an all- encompassing review of pa-
tients treated with direct oral anticoagulant (DOAC) 
for cerebral venous thrombosis (CVT).
 ► Given the heterogeneity of the literature, a risk of 
bias analysis was performed.
 ► We compared DOAC and standard therapy in one 
randomised controlled trial and five observational 
cohorts.
 ► Meta- analysis comparing different DOACs was not 
possible and is a limitation of this study.
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efficacy in treatment of acute VTE with lower rates of 
intracranial haemorrhage (ICH).9 Guideline recommen-
dations, however, do not support DOAC treatment for 
CVT given the paucity of evidence.6 Recent larger studies 
on DOAC therapy for VTE in atypical locations included 
CVT, thus assessment of the appropriateness of these anti-
coagulants for the treatment of CVT is warranted.10–12
The objective of this study was to review all available 
evidence to assess data on safety and efficacy of DOACs in 
the treatment of CVT.
METHODS
Search strategy and selection criteria
The protocol for this systematic review was registered 
(PROSPERO ID: CRD42017078398)13 and published.14 
We followed Preferred Reporting Items for System-
atic Review and Meta- Analysis Protocols,15 Preferred 
Reporting Items for Systematic Reviews and Meta- 
Analyses16 and Synthesis without meta- analysis (SWiM)17 
guidelines where applicable. The search strategy was iter-
atively developed with assistance of a research librarian 
(RS) and is available in the supplement (online supple-
mental appendix 1. We searched Ovid MEDLINE, 
Embase and the Cochrane Central Register of Controlled 
Trials for original reports of patients with a diagnosis of 
CVT treated with a DOAC up to 18 November 2020. We 
included all available peer- reviewed studies including 
RCTs, prospective or retrospective observational cohorts, 
case series and case studies. Studies without follow- up data 
were excluded. Two authors (GB and JG) independently 
reviewed titles and abstracts for inclusion.
Data items
Study type and number of patients were collected. Patient 
data included age, sex and medical history; CVT infor-
mation included location of venous thrombosis and ICH; 
and DOAC data included type, dosage, timing of initia-
tion after immediate therapy and duration of treatment. 
Safety outcomes included mortality, occurrence of intra-
cranial and extracranial bleeding as defined by authors 
and any other reported adverse events. Efficacy outcomes 
included recurrent CVT, recanalisation rates and disability 
measured by the modified Rankin Scale (mRS). The mRS 
is a six- point scale ranging from 0 (no symptoms) to 6 
(death), with a score of 2 indicating slight disability but 
able to look after own affairs without assistance.18 When 
applicable, authors were contacted for further data.
Risk of bias analysis
We used the Cochrane Risk of Bias Tool for randomised 
trials;19 the Newcastle Ottawa Scale for observational 
cohorts;20 and Joanna Briggs Institute (JBI) Critical 
Appraisal Checklist for case studies and case series.21 The 
Grading of Recommendations, Assessment, Development 
and Evaluations (GRADE) framework was used to assess 
the certainty of absolute treatment effects.22
Statistical analysis
Data were reported as counts and proportions for dichot-
omous data, medians and ranges for non- normally distrib-
uted continuous data, or means with SD for normally 
distributed continuous data. We reported risk ratios 
(RRs) with 95% CIs and study heterogeneity (I2) wher-
ever possible. Case series and case report outcomes are 
presented as pooled descriptive statistics for each DOAC. 
Statistics were performed using STATA/IC V.15.1 and 
RevMan V.5.4.1.
Patient and public involvement




Of 1843 titles, 33 studies met inclusion criteria (figure 1), 
representing 279 patients with CVT treated with a DOAC 
listed in table 1. We identified one RCT consisting of 60 
patients treated with dabigatran and 60 patients treated 
with warfarin;23 five observational cohorts of 101 patients 
treated with rivaroxaban (n=80), dabigatran (n=11) 
and apixaban (n=10) compared with warfarin (n=301) 
or LMWH (n=14);24–28 six case series of patients treated 
with rivaroxaban (n=44), dabigatran (n=36) and apix-
aban (n=13);29–34 and 21 case studies of rivaroxaban 
(n=8), dabigatran (n=8), apixaban (n=4) and edoxaban 
(n=5).35–55 The clinical characteristics and outcomes of 
the patients are listed in table 2.
Dabigatran
A total of 115 patients (41.2%) were treated with dabiga-
tran. In a multicentre, open- label, blinded end- point RCT 
by Ferro et al, ‘A Clinical Trial Comparing Efficacy and 
Safety of Dabigatran Etexilate With Warfarin in Patients 
With Cerebral Venous and Dural Sinus Thrombosis’ 
(RE- SPECT CVT, NCT02913326)23 patients were initially 
treated with LMWH or UFH for 5–15 days, followed by 
dabigatran 150 mg twice daily for 24 weeks. No patient 
died in the study. No new ICH occurred in the dabigatran 
group, while two occurred in the warfarin group. There 
were seven patients (11.7%) who discontinued dabiga-
tran due to adverse events: one for worsening CVT- related 
baseline ICH, one intestinal haematoma and five non- 
bleeding adverse events. None of the four (6.7%) patients 
who discontinued warfarin did so due to adverse events. 
Follow- up data on 55 dabigatran- treated patients showed 
no radiographic CVT improvement in 40%, compared 
with 33% treated with warfarin (RR 1.22, 95% CI 0.74 to 
2.03, p=0.44). At 24 weeks, a favourable mRS of 0–2 was 
reported in 58 of 59 (98.3%) in the dabigatran group and 
56 of 58 (96.6%) in the warfarin group (p=0.62).
Descriptive studies of dabigatran reported an addi-
tional 44 patients. A case series by Mendonça et al33 
provided patient- level data on request for 18 patients 
treated initially with UFH for a median 13 days followed 
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by dabigatran for a median 6 months, 150 mg twice 
daily in 16 patients (89%) and 110 mg twice daily in two 
patients (11%). No deaths or ICH were reported, though 
one patient (6%) had a major intestinal bleed and one 
(6%) had minor intestinal bleed. At 6 months, mRS of 
0 or 1 was reported in 15 patients (83%) and one (6%) 
had mRS of 3 (moderate disability, dependent on others 
but can walk). Rusin et al31 reported pooled data on 18 
patients with dabigatran, 150 mg twice daily in 16 and 
110 mg twice daily in 2, as well as rivaroxaban 20 mg daily 
in 10 and apixaban 5 mg twice daily in eight patients 
treated for a median of 8.5 months. During the 30- month 
follow- up, no death or ICH was reported, but three 
(8.3%) had major bleeding. Recurrent CVT occurred in 
two (5.6%) at 5 and 20 months after DOAC completion. 
Complete recanalisation occurred in 10 on dabigatran 
(55.6%), 6 on rivaroxaban (60.0%) and 6 on apixaban 
(50.0%). At 6–12 months after CVT, an excellent mRS of 
0 or 1 was reported in 24 patients (66.7%), independent 
mRS of 2 in 10 (27.8%) and two (5.6%) had significant 
disability. Case studies of dabigatran reported one new 
ICH due to development of a dural arteriovenous fistula 
(DAVF) despite a reportedly complete recanalisation of 
their CVT37 and one myocardial infarction in the context 
of double thrombophilia from both plasminogen acti-
vator inhibitor-1 (PAI-1) 4G/4G homozygous genotype 
and protein C and S deficiency and required transition to 
warfarin.39 Otherwise, no patient had reported mortality, 
and all eight case studies reported an mRS of 0 or 1 after 
treatment.37–39 52–55
Rivaroxaban
A total of 132 patients (47.3%) were treated with rivar-
oxaban. Five observational cohorts pooled 101 DOAC- 
treated patients, 80 (79%) on rivaroxaban, 11 (11%) 
on dabigatran 150 mg twice daily and 10 (10%) on apix-
aban, compared with 315 on standard therapy with 301 
(96%) warfarin and 14 (4%) LMWH.24–28 Patients were 
treated with DOAC for an average 8.1 months and with 
standard therapy for 9.8 months. Deaths were reported in 
four patients treated with a DOAC compared with six on 
standard therapy (RR 2.12, 95% CI 0.29 to 15.59, p=0.46, 
Figure 1 PRISMA flow diagram of studies included in systematic review. CVT, cerebral venous thrombosis; DOAC, direct oral 
anticoagulant; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta- Analyses.
 on F









pen: first published as 10.1136/bm





4 Bose G, et al. BMJ Open 2021;11:e040212. doi:10.1136/bmjopen-2020-040212
Open access 
I2=49%) (figure 2). Hsu et al24 reported two deaths after 
DOAC therapy (25%): one in hospital from respiratory 
failure postaspiration in a patient treated with apixaban, 
and another due to metastatic lung cancer 1 year after 
CVT. Wasay et al27 reported two deaths in their DOAC 
group (4%): one prior to discharge and one prior to 
6- month follow- up, and four deaths in their warfarin 
group (6%): three prior to discharge and one prior to 
Table 1 Published patients with CVT treated with DOAC
Study Year Location Anticoagulant N Study type
Bando et al43 2020 Japan Edoxaban 1 Case report





Saito et al44 2020 Japan Edoxaban 1 Case report
Sugiyama et al45 2020 Japan Edoxaban 1 Case report
Chiu et al39 2020 USA Dabigatran 1 Case report





Bolaji et al46 2020 UK Edoxaban 1 Case report
Ferro et al23 2019 Multicentre Dabigatran 60 Randomised controlled trial












Huang et al37 2019 China Dabigatran 1 Case report





Hu et al38 2019 China Dabigatran 1 Case report







Shankar Iyer et al30 2018 India Rivaroxaban 20 Case series
Yasushi42 2017 Japan Edoxaban 1 Case report
Sui et al48 2017 China Rivaroxaban 1 Case report
Becerra et al52 2017 Argentina Dabigatran 1 Case report
Budhram et al51 2017 Canada Rivaroxaban 1 Case report
Cappellari et al32 2017 Italy Rivaroxaban 4 Case series
Hsu et al50 2017 China Rivaroxaban 1 Case report
Inche Mat et al55 2017 Malaysia Dabigatran 1 Case report
Rao et al41 2017 USA Apixaban 3 Case report
Talamo et al40 2017 USA Apixaban 1 Case report





Anticoli et al34 2016 Italy Rivaroxaban 6 Case series
Cho et al49 2016 South Korea Rivaroxaban 1 Case report
Micieli et al47 2016 Canada Rivaroxaban 1 Case report
Mendonça et al33 2015 Portugal Dabigatran 18 Case series
Mutgi et al36 2015 USA Rivaroxaban 2 Case report
Sugie et al35 2015 Japan Rivaroxaban 1 Case report
Mathew et al54 2013 India Dabigatran 1 Case report
Hon et al53 2012 Hong Kong Dabigatran 2 Case report
CVT, cerebral venous thrombosis; DOAC, direct oral anticoagulants.
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6- month follow- up. The causes of death were not reported. 
Herweh et al28 reported two deaths in their cohort (2%), 
and on request for patient- level data, none were treated 
with a DOAC. No significant difference between DOAC 
or standard therapy was reported for ICH (1% vs 2.5%, 
RR 0.72, 95% CI 0.18 to 2.85, p=0.64, I2=0%), recurrent 
CVT (5.7% vs 11.7%, RR 0.45, 95% CI 0.05 to 4.40, p=0.49, 
I2=54%) or incomplete recanalisation (35.8% vs 26.5%, 
RR 0.84, 95% CI 0.58 to 1.21, p=0.35, I2=0%) available 
in the supplement (online supplemental appendix 2). A 
favourable functional outcome of mRS 0–2 was reported 
in 61 of 69 (88.4%) DOAC- treated patients compared 
with 126 of 156 (80.7%) on standard therapy (RR 1.13, 
95% CI 1.02 to 1.25, p=0.02, I2=0%) (figure 3).
Descriptive studies of rivaroxaban reported an addi-
tional 52 patients. A case series by Shankar Iyer et al30 
treated 20 stable patients with rivaroxaban acutely at 15 mg 
twice daily for 3 weeks followed by 20 mg daily. At 6- month 
follow- up, no patient died or discontinued rivaroxaban. 
There was no ICH or adverse effects reported. There was 
recanalisation in all patients and 19 (95%) reported mRS 
of 0 or 1, with mRS of 2 in only one (5%). Other case 
series and studies of rivaroxaban reported no mortality or 
ICH, and all had mRS 0 or 1 at follow- up.32 34–36 47–51 The 
dosing of rivaroxaban was variable: most received 20 mg 
daily after initial standard therapy,32 one with antiphos-
pholipid syndrome received 15 mg daily after suffering a 
stroke with haemorrhagic transformation 3 months after 
Figure 2 Forest plot comparing all- cause mortality between direct oral anticoagulant (DOAC) and standard therapy (warfarin, 
low molecular weight heparin or unfractionated heparin) for cerebral venous thrombosis.
Figure 3 Forest plot comparing favourable functional outcome of modified Rankin Scale (mRS) of 0–2 between direct oral 
anticoagulant (DOAC) and standard therapy (warfarin, low molecular weight heparin or unfractionated heparin) for cerebral 
venous thrombosis.
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starting warfarin for CVT,35 two received 10 mg daily in 
the context of Crohn’s disease49 and pegylated aspar-
aginase for acute lymphoblastic leukaemia,48 and one 
was treated with 5 mg daily, in conjunction with plasma 
exchange (PLEX), for concurrent anti-N- methyl- D- 
aspartate (NMDA) receptor encephalitis.50 One patient 
was initially treated with rivaroxaban 15 mg twice daily 
and was then switched to dabigatran due to low anti- Xa 
levels in the context of concurrent phenytoin use for 
seizures secondary to CVT.52
Apixaban
Apixaban has been reported in 27 patients (9.7%).29 40 41 
In the series reported by Covut et al29, five patients were 
treated with apixaban and four patients with rivaroxaban 
after a median 3 days of UFH and continued for a median 
of 12 months. No patient died or had new ICH during the 
follow- up, nor switched off their DOAC. One patient was 
switched onto apixaban due to gastrointestinal bleeding 
on warfarin and another was switched onto rivaroxaban 
30 days after starting warfarin due to INR fluctuations. 
No recanalisation was reported in three patients (60%) 
on apixaban and one patient (25%) on rivaroxaban. 
At 6- month follow- up, mRS was 0 or 1 in eight patients 
(89%) and one patient had persistent mRS of 4 (unable 
to walk unassisted). The other case studies of apixaban 
indicate that all four patients had mRS of 0–1 after treat-
ment, with no mortality or new ICH. Apixaban dosing 
was 5 mg twice daily for all patients, though one received 
10 mg twice daily initially for 7 days in the context of T 
cell acute lymphoblastic leukaemia treated with pegylated 
asparaginase.40
Edoxaban
Edoxaban was reported in case studies of five patients 
(1.8%).37–41 No death, ICH, recurrent CVT or incom-
plete recanalisation was reported, and all patients had a 
good functional outcome. Two of the reported patients 
developed CVT in the context of COVID-19 infection and 
recovered without neurological sequelae.45 46
Risk of bias
The risks of bias analyses are available in the supple-
ment (online supplemental appendix 3). In RE- SPECT 
CVT, patients and treating teams were aware of treat-
ment allocation.23 No observational cohort controlled for 
confounders. Treatment initiation time was not reported 
in two observational cohorts, and follow- up duration was 
not standardised.24 26 The case series and case studies are 
moderately biased based on JBI Critical Appraisal, given 
lack of reporting completeness. Based on the currently 
available studies, the GRADE certainty is low for the abso-
lute treatment effect.
DISCUSSION
We found that since the approval of DOAC for treatment 
of VTE, 279 patients treated with DOAC for CVT have 
been published with follow- up data. Of these patients, 
42% are reported in case studies or case series, 36% in 
five observational cohorts and 22% in one RCT. There 
were 200 patients (72%) published in 2019 and 2020, 
suggesting that practitioner comfort for DOAC use in 
CVT is improving despite a lack of guideline recom-
mendations.6 A recent survey of Canadian neurologists 
and haematologists suggests interest in the utilisation of 
DOAC for treatment of CVT, and the increasing reports 
support this trend.56
Outcomes of DOAC compared with standard therapy
Currently, warfarin is supported by guidelines despite no 
RCT evidence of superiority or non- inferiority to LMWH 
or UFH. The benefits of the DOAC over warfarin include 
reduced dose adjustments due to drug and food interac-
tions, no need for INR monitoring to ensure therapeutic 
range and, in the case of dabigatran, the availability of 
a reversal agent. Furthermore, even when closely moni-
tored in a clinical trial setting, patients on warfarin for 
CVT were in the therapeutic INR range only 66% of the 
time,23 suggesting better anticoagulation may be achieved 
with DOAC. Overall safety of DOAC was reassuring, with 
recurrent CVT, new ICH and death only reported in 
observational cohorts at rates similar to standard therapy 
and within the expected range of treated CVT.2 Further-
more, of the DOAC- treated patients who died, two of four 
deaths occurred after discharge, including one related 
to underlying metastatic cancer that would not suggest 
DOAC- related mortality.24 Efficacy was also promising 
with 93% of DOAC- treated patients attaining a favourable 
outcome of mRS from 0 to 2 compared with 85% of those 
on standard therapy. Compared with standard therapy in 
the observational cohorts, this value was higher for DOAC- 
treated patients. However, utilisation of DOAC in less 
severe CVT cannot be ruled out as a confounding factor 
since the observational cohorts did not have comparable 
standard treatment groups.
A meta- analysis published by Lee et al57 showed similar 
results to our review with no difference between DOAC 
or warfarin for recanalisation rates or major bleeding; 
however, their review analysed an ‘excellent’ mRS 
outcome of 0–1 and found no difference, while our study 
analysed a ‘favourable’ mRS of 0–2 and found a difference 
in the observational cohorts. The dichotomy of a favour-
able mRS has been debated, with mRS greater than two 
shown to be related to 1- year mortality, as well as being 
an independence cut- off for entry to certain endovascular 
trials.58–60 The apparent discrepancy may also relate to 
two of their analysed observational cohort studies (Geis-
büsch et al61 and Herweh et al28) potentially including 
patients from the same institution during overlapping 
time periods (January 2012–December 2013 and January 
1998–September 2014, respectively). To clarify, we were 
able to contact the authors from these studies and obtain 
patient- level data, which led to the exclusion of Geisbüsch 
et al61 due to duplicate patient data. Furthermore, we have 
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updated the search to include an additional two cohorts 
published in 2020.
An ongoing RCT out of University of British Columbia, 
the ‘Study of Rivaroxaban for CeREbral Venous Throm-
bosis’ (SECRET, NCT03178864), is currently recruiting 
an estimated 50 participants comparing rivaroxaban with 
standard anticoagulation of LMWH, UFH or warfarin, 
expected to be completed December 2021.62 Another 
RCT, ‘Rivaroxaban vs Warfarin in CVT Treatment’ 
(RWCVT, NCT04569279) out of Damascus University 
has completed enrollment of 71 patients though not yet 
published results.63 Results of these studies will be useful 
for future guideline recommendations for DOAC use in 
CVT compared with standard therapy.6
Comparison between different DOAC
Our search yielded no randomised trials comparing 
different DOAC against each other, thus no formal meta- 
analysis comparing different DOAC was possible. Dabiga-
tran was compared against warfarin in the only published 
RCT specifically looking at CVT to date; however, the 
most commonly reported DOAC was rivaroxaban, 
possibly suggesting physician comfort with this medica-
tion. Results from RWCVT and SECRET will help validate 
safety and efficacy of rivaroxaban and allow more defini-
tive comparison with dabigatran from RE- SPECT CVT.62
The timing of DOAC initiation after acute treatment 
with LMWH or UFH ranged from 5 to 15 days for the 
RCT and from 3 to 12 days for the observational cohorts. 
The descriptive studies had more variability in DOAC 
initiation, ranging from acutely after CVT diagnosis, to 
as far as 3 months, making comparisons challenging. The 
dosage of DOAC was also inconsistent, with dabigatran 
dose ranging from 75 mg to 150 mg twice daily in the 
cohort by Wasay et al27 and rivaroxaban dosing between 
5 mg daily and 20 mg daily depending on the study. Both 
ongoing RCTs use rivaroxaban after initial acute therapy 
with LMWH or UFH, for SECRET 20 mg daily within 14 
days of CVT diagnosis, and for RWCVT 20 mg or 15 mg, 
depending on creatinine clearance, after a non- specified 
duration of acute therapy. These and future trials should 
help standardise how long initial therapy with LMWH or 
UFH is needed, if at all, prior to using DOAC, as well as if 
initial dosage adjustments are needed.
There were rare adverse events with each DOAC 
therapy. For dabigatran, no deaths were reported, and of 
the patients who experienced bleeding, none were given 
the reversal agent. However, in RE- SPECT CVT, dabiga-
tran was stopped in two patients due to intestinal haema-
toma and worsening of the haemorrhagic component of 
their baseline intracranial lesion.23 Bleeding events on 
rivaroxaban were only reported in the series by Rusin 
et al31 in three patients (8.3%), two on 20 mg daily rivar-
oxaban and one on 110 mg twice daily dabigatran, who 
had heavy menstrual bleedings in two and upper gastro-
intestinal bleeding in one. Other rare adverse events 
include the in- hospital death of a patient treated with 
apixaban who had an aspiration event and respiratory 
failure,24 myocardial infarction while on dabigatran39 and 
DAVF formation 3 months after CVT despite complete 
recanalisation with dabigatran.37 A post hoc analysis 
of the RE- SPECT CVT showed no DAVF formation at 6 
months.64 Two case studies of edoxaban treated patients 
with CVT in the context of COVID-19.45 46 Thrombotic 
complications of COVID-19 has been reported, but the 
safety and efficacy of DOAC in COVID-19 related throm-
bosis specifically has yet to be confirmed.65 66
The efficacy of each DOAC was good for treatment of 
CVT. Recurrent CVT was only reported in four patients 
overall (1.5%), two patients from the cohort Powell et al25 
(11%) and two in the case series Rusin et al31 (5.6%) after 
discontinuation of DOAC. An international long- term 
cohort found the rate of recurrent CVT is as high as 4.4% 
at median 40 months; therefore, long- term follow- up of 
DOAC- treated CVT is needed to determine the ideal 
treatment duration.67 Recanalisation rates varied between 
DOAC treatment at similar rates reported in randomised 
trials of LMWH and UFH to treat CVT3–5 without clear 
reduction of a favourable functional outcome, as previ-
ously demonstrated.28 However, the prognostic value of 
recanalisation has been investigated by a meta- analysis of 
standard therapy, which showed recanalisation occurred 
in up to 85% of patients and was associated with mRS 0 
or 1 (OR 3.3, 95% CI 1.7 to 6.3, p=0.001).68 Further high- 
quality studies will be required to determine if recanali-
sation rates differ between DOACs, as well as if they are 
related to functional outcome.
Limitations
The results of this systematic review should be interpreted 
with caution. The majority of patients were reported in 
retrospective observational cohorts or case studies prone 
to selection bias, confounding and lack of standardisa-
tion in timing of therapy initiation and follow- up dura-
tion. Therefore, pooling and inferential statistical analysis 
was not prudent due to the clinical and methodological 
heterogeneity and conclusions as to how DOAC ther-
apies perform against each other could not be made. 
The risk of bias analysis revealed that RE- SPECT CVT 
has the lowest bias risk given utilisation of a Prospective 
Randomized Open, Blinded End- point (PROBE) design, 
and although the retrospective studies inherently have 
increased bias, most studies were appropriately informa-
tive. Finally, follow- up data and treatment duration were 
limited to a median 6 months; longer term registries for 
safety will be needed to estimate rates of recurrent CVT in 
patients treated with a DOAC.
Unanswered questions and future research
Our systematic review suggests physicians are increasingly 
using DOAC for the treatment of CVT; however, several 
remaining questions require further study. The ideal 
time to start a DOAC after diagnosis of CVT is not known. 
Certain studies first use LMWH or UFH treatment, while 
others used a DOAC acutely. The safety of DOAC use 
in children is not known. The recently published RCT, 
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‘Oral Rivaroxaban in Children With Venous Thrombosis’ 
(EINSTEIN- JR, NCT02234843), investigated paediatric 
cases of any acute VTE and randomised to weight- based 
rivaroxaban or standard anticoagulation showed poten-
tially improved thrombotic burden (OR 1.70, p=0.012) 
and similar safety as adult studies.69 Specific outcomes 
were not reported based on VTE location; however, 74 of 
335 (22%) patients treated with rivaroxaban had CVT, and 
no clear safety concern was identified. Finally, the ideal 
DOAC to use for CVT also requires further study. Results 
from RWCVT and SECRET will help validate safety and 
efficacy of rivaroxaban and allow more definitive compar-
ison with dabigatran from RE- SPECT CVT.62 Although 
dabigatran has the advantage of having a reversal agent, 
idaricizumab, its use in CVT has not been published at 
the current time, so any unique risks in this population 
is unknown.70 Extrapolating conclusions for apixaban or 
edoxaban from studies of different DOAC may give an 
inaccurate risk–efficacy profile, and thus high- quality 
RCT of these treatments are also needed.
Given that CVT is a rare disease, enrolment in these 
large randomised studies is slow, so review of observa-
tional cohorts and smaller studies provide needed infor-
mation. Physicians recognise the benefits of DOACs and 
are increasingly using these medications for treatment 
of CVT despite the lack of guideline recommendations. 
Based on this review, no clear safety concerns are identi-
fied for any particular DOAC, and the available data on 
efficacy is promising. The ideal timing for initiation of 
DOAC after diagnosis of CVT, and the ideal DOAC to use 
for CVT, are remaining questions. The results of future 
RCTs may inform guidelines if no adverse safety signal 
and a similar efficacy to standard therapy is seen.
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Appendix I: Search Strategy 
 
The complete protocol is previously published[1] and is hosted on PROSPERO (ID: 
CRD42017078398).[2] 
 
Ovid MEDLINE(R) ALL 
Strategy:  
 
1. apixaban.mp.  
2. edoxaban.mp.  
3. Dabigatran.mp.  
4. Rivaroxaban.mp.  
5. (doac* or noac*).tw,kw.  
6. ((direct oral or novel) adj3 (anticoagul* or anti coagulat*)).tw.  
7. exp Factor Xa Inhibitors/  
8. Factor Xa Inhibit*.mp.  
9. Antithrombins/ or thrombin inhibit*.mp.  
10. or/1-9  
11. "intracranial embolism and thrombosis"/ or intracranial thrombosis/ or exp sinus thrombosis, 
intracranial/  
12. cvt.tw,kw.  
13. (cerebral veins/ or exp cranial sinuses/) and (thrombosis/ or venous thrombosis/)  
14. ((sinus* or sinovenous or cerebral or cavernous or sagittal venous or sagittal vein* or 
cerebrovenous or cerebro-venous or sigmoid) and thrombo*).tw,kw.  
15. intracran* thrombo*.kw. or (intracran* adj3 thrombo*).tw.  
16. 11 or 12 or 13 or 14 or 15  
17. 10 and 16 
 
 
Database: Embase Classic+Embase 
Strategy:  
 
1. apixaban.mp.  
2. edoxaban.mp.  
3. Dabigatran.mp.  
4. Rivaroxaban.mp.  
5. (doac* or noac*).tw.  
6. ((direct oral or novel) adj3 (anticoagul* or anti coagulat*)).tw.  
7. exp *Factor Xa Inhibitors/   
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14. cvt.tw.  
15. or/11-14  
16. 10 and 15 
 
 
Database: EBM Reviews - Cochrane Central Register of Controlled Trials  
Search Strategy:  
 
1. apixaban.mp.  
2. edoxaban.mp.  
3. Dabigatran.mp.  
4. Rivaroxaban.mp.  
5. (doac* or noac*).tw,kw.  
6. ((direct oral or novel) adj3 (anticoagul* or anti coagulat*)).tw.  
7. exp Factor Xa Inhibitors/  
8. Factor Xa Inhibit*.mp.  
9. Antithrombins/ or thrombin inhibit*.mp.  
10. or/1-9  
11. "intracranial embolism and thrombosis"/ or intracranial thrombosis/ or exp sinus thrombosis, 
intracranial/  
12. cvt.tw,kw.  
13. (cerebral veins/ or exp cranial sinuses/) and (thrombosis/ or venous thrombosis/)  
14. ((sinus* or sinovenous or cerebral or cavernous or sagittal venous or sagittal vein* or 
cerebrovenous or cerebro-venous or sigmoid) and thrombo*).tw,kw.  
15. intracran* thrombo*.kw. or (intracran* adj3 thrombo*).tw.  
16. 11 or 12 or 13 or 14 or 15  
17. 10 and 16 
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